- Home
- Business & Economics
- Economics
- Pharmaceutical Industry and Public Policy in Post-reform India
Pharmaceutical Industry and Public Policy in Post-reform India
List Price:
$73.99
- Availability: Confirm prior to ordering
- Branding: minimum 50 pieces (add’l costs below)
- Check Freight Rates (branded products only)
Branding Options (v), Availability & Lead Times
- 1-Color Imprint: $2.00 ea.
- Promo-Page Insert: $2.50 ea. (full-color printed, single-sided page)
- Belly-Band Wrap: $2.50 ea. (full-color printed)
- Set-Up Charge: $45 per decoration
- Availability: Product availability changes daily, so please confirm your quantity is available prior to placing an order.
- Branded Products: allow 10 business days from proof approval for production. Branding options may be limited or unavailable based on product design or cover artwork.
- Unbranded Products: allow 3-5 business days for shipping. All Unbranded items receive FREE ground shipping in the US. Inquire for international shipping.
- RETURNS/CANCELLATIONS: All orders, branded or unbranded, are NON-CANCELLABLE and NON-RETURNABLE once a purchase order has been received.
Product Details
Author:
Reji K. Joseph
Format:
Paperback
Pages:
252
Publisher:
Taylor & Francis (November 28, 2017)
Language:
English
ISBN-13:
9780815375999
Weight:
16.625oz
Dimensions:
5.4375" x 8.5"
File:
TAYLORFRANCIS-TayFran_260714044205898-20260714.xml
Folder:
TAYLORFRANCIS
List Price:
$73.99
Series:
Critical Political Economy of South Asia
Case Pack:
1
As low as:
$70.29
Publisher Identifier:
P-CRC
Discount Code:
H
Audience:
College/higher education
Country of Origin:
United States
Pub Discount:
30
Imprint:
Routledge India
Overview
This book examines the impact of economic reforms in India on the pharmaceutical industry and access to medicines. It traces the changing production and trade pattern of the industry, research and development (R&D) preferences and strategies of Indian pharmaceutical firms, patent system alongside pricing policy measures and their shortcomings. It also analyses the public health financing system in India driven largely by out-of-pocket expenditure — about 60 per cent — and characterised by very high share of medicines in total health expenditure.
